{"result": {"id": "0cc3e651-25f4-4e10-b183-75c4d7156780", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACTION TRIAL<|>EVENT<|>A clinical trial investigating the effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension>)\n##\n(\"entity\"<|>EUROPA STUDY<|>EVENT<|>A randomized, double-blind, placebo-controlled, multicentre trial evaluating the efficacy of perindopril in reducing cardiovascular events among patients with stable coronary artery disease>)\n##\n(\"entity\"<|>ESC<|>ORGANIZATION<|>European Society of Cardiology, responsible for guidelines on the management of acute coronary syndromes>)\n##\n(\"entity\"<|>PARADISE-MI TRIAL<|>EVENT<|>A clinical trial investigating the effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction>)\n##\n(\"entity\"<|>CHINA CARDIOVASCULAR ASSOCIATION<|>ORGANIZATION<|>An organization maintaining a database and registry for heart failure centers in China>)\n##\n(\"entity\"<|>U.S. DEPARTMENT OF VETERANS AFFAIRS<|>ORGANIZATION<|>A U.S. government department involved in guidelines for intensive blood pressure lowering>)\n##\n(\"entity\"<|>U.S. DEPARTMENT OF DEFENSE<|>ORGANIZATION<|>A U.S. government department involved in guidelines for intensive blood pressure lowering>)\n##\n(\"entity\"<|>AHA/ACC/HFSA<|>ORGANIZATION<|>American Heart Association/American College of Cardiology/Heart Failure Society of America, responsible for guidelines on the management of heart failure>)\n##\n(\"entity\"<|>Lubsen J<|>PERSON<|>Researcher involved in the ACTION trial>)\n##\n(\"entity\"<|>Fox KM<|>PERSON<|>Researcher involved in the EUROPA study>)\n##\n(\"entity\"<|>Roffi M<|>PERSON<|>Researcher involved in the ESC guidelines for acute coronary syndromes>)\n##\n(\"entity\"<|>McMurray JJ<|>PERSON<|>Researcher involved in studies on angiotensin-neprilysin inhibition versus enalapril in heart failure>)\n##\n(\"entity\"<|>Pfeffer MA<|>PERSON<|>Researcher involved in studies on angiotensin receptor-neprilysin inhibition in acute myocardial infarction>)\n##\n(\"entity\"<|>Mehran R<|>PERSON<|>Researcher involved in the PARADISE-MI trial>)\n##\n(\"entity\"<|>Soenarta AA<|>PERSON<|>Researcher involved in studies on hypertension and cardiac involvement in Asia>)\n##\n(\"entity\"<|>Cai A<|>PERSON<|>Researcher involved in the China Cardiovascular Association Database-Heart Failure Center Registry>)\n##\n(\"entity\"<|>D'Anci KE<|>PERSON<|>Researcher involved in systematic reviews for the U.S. Department of Veterans Affairs/Department of Defense guidelines>)\n##\n(\"entity\"<|>Selvaraj S<|>PERSON<|>Researcher involved in studies on systolic blood pressure in heart failure with preserved ejection fraction>)\n##\n(\"entity\"<|>Miao H<|>PERSON<|>Researcher involved in studies on hypertension management in heart failure>)\n##\n(\"entity\"<|>McDonagh TA<|>PERSON<|>Researcher involved in the 2021 ESC guidelines for heart failure>)\n##\n(\"entity\"<|>Heidenreich PA<|>PERSON<|>Researcher involved in the 2022 AHA/ACC/HFSA guidelines for heart failure>)\n##\n(\"relationship\"<|>Lubsen J<|>ACTION TRIAL<|>Lubsen J was a researcher involved in the ACTION trial<|>8>)\n##\n(\"relationship\"<|>Fox KM<|>EUROPA STUDY<|>Fox KM was a researcher involved in the EUROPA study<|>8>)\n##\n(\"relationship\"<|>Roffi M<|>ESC<|>Roffi M was involved in the ESC guidelines for acute coronary syndromes<|>8>)\n##\n(\"relationship\"<|>McMurray JJ<|>PARADISE-MI TRIAL<|>McMurray JJ was involved in studies related to the PARADISE-MI trial<|>7>)\n##\n(\"relationship\"<|>Pfeffer MA<|>PARADISE-MI TRIAL<|>Pfeffer MA was a researcher involved in the PARADISE-MI trial<|>8>)\n##\n(\"relationship\"<|>Mehran R<|>PARADISE-MI TRIAL<|>Mehran R was a researcher involved in the PARADISE-MI trial<|>8>)\n##\n(\"relationship\"<|>Soenarta AA<|>CHINA CARDIOVASCULAR ASSOCIATION<|>Soenarta AA was involved in studies related to the China Cardiovascular Association<|>6>)\n##\n(\"relationship\"<|>Cai A<|>CHINA CARDIOVASCULAR ASSOCIATION<|>Cai A was involved in the China Cardiovascular Association Database-Heart Failure Center Registry<|>8>)\n##\n(\"relationship\"<|>D'Anci KE<|>U.S. DEPARTMENT OF VETERANS AFFAIRS<|>D'Anci KE was involved in systematic reviews for the U.S. Department of Veterans Affairs guidelines<|>7>)\n##\n(\"relationship\"<|>D'Anci KE<|>U.S. DEPARTMENT OF DEFENSE<|>D'Anci KE was involved in systematic reviews for the U.S. Department of Defense guidelines<|>7>)\n##\n(\"relationship\"<|>Selvaraj S<|>AHA/ACC/HFSA<|>Selvaraj S was involved in studies related to the AHA/ACC/HFSA guidelines<|>6>)\n##\n(\"relationship\"<|>Miao H<|>CHINA CARDIOVASCULAR ASSOCIATION<|>Miao H was involved in studies related to the China Cardiovascular Association<|>6>)\n##\n(\"relationship\"<|>McDonagh TA<|>ESC<|>McDonagh TA was involved in the 2021 ESC guidelines for heart failure<|>8>)\n##\n(\"relationship\"<|>Heidenreich PA<|>AHA/ACC/HFSA<|>Heidenreich PA was involved in the 2022 AHA/ACC/HFSA guidelines for heart failure<|>8>)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559018, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1450, "prompt_tokens": 2863, "total_tokens": 4313, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1071}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ) :435- 443.\n[557]  LubsenJ, WagenerG, KirwanBA, etal. Effectoflong-acting nifedipineon mortality and cardiovascular morbidity in patients with symptomaticstableanginaand hypertension: theACTION  trial[J]. J Hypertens,2005,23(3) :641-648.\n[558]  Fox KM.  Efficacy of perindoprilin reduction of cardiovascular eventsamongpatientswith stable coronary artery disease: ran- domised,   double-blind,   placebo-controlled,   multicentre  trial (theEUROPA study)[J]. Lancet,2003,362(9386) :782-788.\n[559]  RoffiM, PatronoC, ColletJP, etal.  2015 ESC guidelines for the managementofacutecoronarysyndromesinpatientspresen- tingwithoutpersistentST-segmentelevation: taskforceforthe managementofacutecoronary syndromesinpatients presenting withoutpersistentST-segmentelevationoftheEuropeanSociety ofCardiology(ESC)[J]. EurHeartJ,2016,37(3) :267-315.\n[560]  McMurrayJJ, PackerM, DesaiAS, etal.  Angiotensin-neprily- sin inhibition versusenalaprilin heartfailure[J]. NEnglJ Med,  2014,371(11) :993-1004.\n[561]  PfefferMA, ClaggettB, LewisEF, etal. Angiotensinreceptor- neprilysin inhibition in acutemyocardialinfarction[J]. N EnglJ Med,2021,385(20) :1845-1855.\n[562]  Mehran R, StegPG, PfefferMA, etal. Theeffectsofangioten- sin receptor-neprilysininhibitiononmajorcoronaryeventsinpa- tients with  acute myocardial infarction:  insights from  the PARADISE-MItrial[J]. Circulation,2022,146(23) :1749-1757.\n[563]  SoenartaAA, Buranakitjaroen P, ChiaYC, etal. An overview  ofhypertension and cardiacinvolvementin Asia: focus on heart failure[J]. J Clin Hypertens(Greenwich) ,2020,22(3) :423-430.\n[564]  国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作 组.  2020中国心力衰竭医疗质量控制报告[J]. 中华心力衰竭和 心肌病杂志 ,2020,4(4) :237-249.\n[565]  CaiA, QiuW , ZhouY, etal. Clinicalcharacteristicsand1-year outcomes in hospitalized patients with heart failure with pre- served ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry[J]. Eur J HeartFail,2022,24(11) :2048-2062.\n[566]  D'AnciKE, Tipton K, Hedden-GrossA, etal.  Effectofinten- siveblood pressurelowering on cardiovascularoutcomes: asys-\n\n\n　tematicreview prepared forthe 2020U. S.  DepartmentofVet- eransAffairs/U. S.  DepartmentofDefense Guidelines[J]. Ann Intern Med,2020,173(11) :895-903.\n[567]  SelvarajS, ClaggettBL, B?hm M, etal. Systolicbloodpressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan[J]. JAm CollCardiol, 2020, 75(14) : 1644- 1656.\n[568]  Miao H, ZouC, YangS, etal. Targetsandmanagementofhy- pertension inheartfailure: focusingonthestagesofheartfailure [J]. J Clin Hypertens(Greenwich) ,2022,24(9) :1218-1225.\n[569]  国家心血管病中心 , 国家心血管病专家委员会心力衰竭专业委 员会 , 中国医师协会心力衰竭专业委员会 ,等.  国家心力衰竭指 南 2023[J]. 中华心力衰竭和心肌病杂志(中英文) ,2023, 7(4) : 215-311.\n[570]  McDonagh TA, MetraM, Adamo M, et al.  2021 ESC guide- linesforthe diagnosis and treatmentofacute and chronic heart failure[J]. EurHeartJ,2021,42(36) :3599-3726.\n[571]  Heidenreich PA, Bozkurt B, Aguilar D,  et al.  2022 AHA/ ACC/HFSA guidelineforthe managementofheartfailure: ex- ecutivesummary: a reportoftheAmerican CollegeofCardiolo- gy/American HeartAssociationjointcommitteeonclinicalprac- ticeguidelines[J].\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_d8f31ff432b667fdc272816795d422e7d094e585ef24fba7a8b6df2e86c1b63c_v2"}